Hydroxychloroquine study withdrawn over data concerns
The anti-malaria drug has been touted as a “miracle cure” for Covid-19, but the scientific evidence so far is confusing.
Associated Press
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
This content was published on
2 minutes
swissinfo.ch/jc
The article, published in the Lancet medical journal on May 22, was by Harvard Medical School, the University of Utah and Switzerland’s University Hospital Zurich. It found that antimalarial drugs hydroxychloroquine and a similar drug chloroquine showed no benefit against Covid-19 and could even increase the risk of heart arrhythmia and death.
But three of the four authors, including Frank Ruschitzka of the University Hospital of Zurich, have now retracted it.
On Thursday, they said that Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and that they “can no longer vouch for the veracity of the primary data sources”. The fourth author of the study, Sapan Desai who is chief executive of Surgisphere, declined to comment on the retraction, according to Reuters.
In a June 5 update to its original press release, Zurich University Hospital department of cardiology said it was “only called in by Harvard Medical School to co-author the paper during the evaluation phase” and “was not involved in the provision of the data by the company Surgisphere or in the evaluation of the data collection”. “Prof. Ruschitzka had no contact with the company,” it adds. “After reservations became known, the authors immediately requested an external audit.”
Controversy
The antimalarial drug has been surrounded by controversy. Claimed by French professor Didier Raoult to be a miracle cure for the new coronavirus, it has also been touted by US President Donald Trump and Brazilian President Jair Bolsonaro. The Lancet article caused the suspension of several studies into its use for Covid-19.
At the height of the pandemic in March, Swiss hospitals all had their own policies with regard to administration of the drug, according to data gathered by Swiss television RTS. In mid-May most of the big hospitals harmonised their practise, deciding to stop using chloroquine to treat Covid-19 except for patients taking part in clinical trials.
The World Health Organization paused hydroxychloroquine trials after The Lancet study was released but said on Wednesday it was ready to resume trials.
Popular Stories
More
Swiss oddities
Mennonite movement turns 500 in Zurich, where it all began
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
The Fête de l'Epouvantail (scarecrow festival) is celebrating its 30th anniversary and returns to Denens in canton Vaud for its seventh edition from July 10-20.
This content was published on
A 35-year-old man has died in a work accident at the valley station of the Heimwehfluh toboggan run in Matten near Interlaken, canton Bern.
This content was published on
The Swiss embassy in Tehran re-opened on Sunday after being closed on June 20 owing to the unstable situation in the country.
This content was published on
Queen Maxima of the Netherlands and her youngest daughter Princess Ariane attended the Netherlands' women's European Championship football match against Wales in Switzerland on Saturday.
Swiss want to better protect military airfields from spying
This content was published on
Swiss Defence Minister Martin Pfister says he wants to better protect Swiss military airfields against espionage activities.
Man charged with flying drone at women’s Euro 2025
This content was published on
A man flew a drone around the venue on Wednesday evening during the first match of the Women's EURO 2025 in St. Gallen. The 30-year-old violated the absolute ban on flying during match days. He was reported to the police.
More than 250 Swiss companies sign CO2 reduction initiative
This content was published on
A total of 257 companies from Switzerland have signed up to the Science Based Targets Initiative (SBTi). In doing so, they are committing to CO2 reduction targets that are compatible with the Paris Climate Agreement.
Swiss accident prevention group sees federal targets at risk
This content was published on
The Swiss government's target for accident figures is at risk, reckons Mario Cavegn, member of the executive board of the Swiss Council for Accident Prevention.
Feminicide: Swiss justice minister calls for electronic monitoring
This content was published on
Swiss Justice Minister Beat Jans has called for electronic monitoring and an ankle bracelet warning system for perpetrators of violence against women.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Study finds hydroxychloroquine linked to higher death rate in Covid-19 patients
This content was published on
An international research team led by the University Hospital of Zurich and Harvard Medical School finds controversial antimalarial drugs show no benefit against Covid-19.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.